Aethlon Medical Inc (AEMD) Stock Analysis and Metrics

Aethlon Medical

NASDAQ: AEMD

$0.59 ▼ -0.01 (-1.75%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7,224.60

P/E-0.05

Div. Yield0.00

Add ratio to table…

About

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier®, a clinical stage immunotherapeutic device designed to remove harmful extracellular vesicles and enveloped viruses from the bloodstream. The company's technology utilizes a lectin based affinity mechanism to capture pathogens and disease associated vesicles, with applications in oncology, life threatening viral infections, and organ transplantation. Aethlon Medical, Inc. has received Breakthrough Device designation from the U. S. Food and Drug Administration for two indications: treatment of advanced or metastatic cancer unresponsive to standard therapies, and treatment of life threatening viruses lacking approved therapies. The company conducts preclinical and clinical research to advance the Hemopurifier toward potential commercialization. The company's executive offices are located in San Diego, California.

Aethlon Medical, Inc. currently does not generate product revenue as the Hemopurifier remains in clinical development and has not yet received regulatory approval for commercial sale. The company's operations are financed primarily through research and development activities, which are supported by cash reserves and occasional financing arrangements. As of the most recent fiscal year, research and development expenses amounted to approximately $2,212,000, reflecting the company's focus on advancing its therapeutic platform. The company also pursues grant funding and strategic collaborations to support its research programs.

The company does not report any operating segments.

Aethlon Medical, Inc. operates in a highly competitive landscape that includes firms developing blood filtration technologies and therapeutic interventions for cancer and infectious diseases. A notable competitor mentioned in the filing is ExThera Medical Corporation, which produces blood filters targeting similar pathogen removal. The company's competitive advantages stem from its proprietary lectin based affinity technology, the Breakthrough Device designations that facilitate regulatory pathways, and its demonstrated ability to capture a broad range of enveloped viruses and extracellular vesicles in preclinical models. Additionally, Aethlon Medical, Inc. leverages its intellectual property portfolio, which includes multiple issued patents and pending applications, to protect its core technology.

The company collaborates with a variety of hospitals and research institutions to conduct its clinical trials and preclinical studies. Specific partners include Royal Adelaide Hospital, Pindara Private Hospital, GenesisCare North Shore Hospital in Australia, Medanta Medicity Hospital in India, DaVita MedCenter Dialysis in Houston, Texas, Apollo Hospital, Fortis Hospital in India, and the University of Pittsburgh in the United States. These relationships provide Aethlon Medical, Inc. with access to patient populations, clinical expertise, and trial sites necessary for advancing the Hemopurifier through developmental stages. The company does not currently sell products to end users, as its focus remains on establishing safety and efficacy data.

Investment Thesis

▲ Bull case

Aethlon Medical's strategic review process with Maxim Group LLC represents a significant unrecognized catalyst that the market is underestimating, as the engagement followed preliminary inbound interest from potential transaction partners and could lead to value-accretive partnerships, mergers, or acquisitions. The company's execution of development activities, including completion of the second cohort in its Australian oncology trial with safety data pending review by the independent Data Safety Monitoring Board, demonstrates operational progress that may not be fully reflected in the current valuation. The Hemopurifier's FDA Breakthrough Device designation for both advanced/metastatic cancer unresponsive to standard care and life-threatening viruses lacking approved therapies provides a dual-pathway regulatory advantage that remains undervalued, particularly as the company advances toward potential commercialization in oncology units through compatibility research with Stavro's SLAMB system, which could eliminate the need for dialysis catheters and nephrologist supervision. Recent cost optimization efforts, evidenced by a 26.9% decline in operating expenses during the nine months ended December 31, 2025, show management's ability to extend cash runway while advancing clinical programs, with approximately $7.0 million in cash as of December 31, 2025 supporting operations into mid-2026. The ongoing monitoring of the Bundibugyo Ebola outbreak in Africa presents a near-term catalyst for potential emergency-use deployment of the Hemopurifier, building on prior successful treatment of a critically ill patient during the 2014 Ebola outbreak where viral load decreased from 400,000 to 1,000 copies per milliliter after a single 6.5-hour treatment, with the device capturing an estimated 242 million virions and the patient ultimately recovering.

▼ Bear case

Aethlon Medical faces substantial risks that the market is overlooking, primarily stemming from its precarious financial position and reliance on dilutive financing to sustain operations, as evidenced by the increase in common shares outstanding from 258,531 at March 31, 2025 to 973,213 at December 31, 2025—a nearly 276% rise driven by capital raises that severely diluted existing shareholders while the accumulated deficit grew from $(167,954,817) to $(173,222,020) over the same period. The company's inability to achieve profitability is structural, with operating losses widening to $2.06 million for Q3 FY26 compared to $1.81 million in the prior year period, and nine-month operating expenses remaining high at $5.36 million despite cost-cutting efforts, indicating that expense reductions are insufficient to offset the fundamental lack of revenue from its investigational Hemopurifier device. Clinical development timelines remain highly uncertain, as the Australian oncology trial's progression to Cohort 3 depends on enrollment of only 9 to 18 patients across three sites, a process vulnerable to delays that could push pivotal data collection beyond management's expected timelines, while the absence of any definitive strategic transaction timeline from the Maxim Group engagement increases the risk of prolonged uncertainty without near-term value realization. Regulatory pathways for both oncology and infectious disease indications remain unproven, with the Breakthrough Device designation only expediting FDA interaction without guaranteeing approval, and the open IDE status requiring successful completion of clinical trials before any PMA study can commence—each step fraught with potential failure due to device performance issues, patient enrollment challenges, or unforeseen regulatory changes. The company's dependence on emergency-use or compassionate-use protocols for Ebola deployment, as seen in the 2014 Frankfurt case, creates unreliable revenue streams and scalability challenges, particularly since no approved therapies exist for the Bundibugyo strain but widespread adoption would require overcoming significant logistical, institutional approval, and patient protection procedure hurdles in resource-constrained outbreak settings.

Aethlon Medical faces substantial risks that the market is overlooking, primarily stemming from its precarious financial position and reliance on dilutive financing to sustain operations, as evidenced by the increase in common shares outstanding from 258,531 at March 31, 2025 to 973,213 at December 31, 2025—a nearly 276% rise driven by capital raises that severely diluted existing shareholders while the accumulated deficit grew from $(167,954,817) to $(173,222,020) over the same period. The company's inability to achieve profitability is structural, with operating losses widening to $2.06 million for Q3 FY26 compared to $1.81 million in the prior year period, and nine-month operating expenses remaining high at $5.36 million despite cost-cutting efforts, indicating that expense reductions are insufficient to offset the fundamental lack of revenue from its investigational Hemopurifier device. Clinical development timelines remain highly uncertain, as the Australian oncology trial's progression to Cohort 3 depends on enrollment of only 9 to 18 patients across three sites, a process vulnerable to delays that could push pivotal data collection beyond management's expected timelines, while the absence of any definitive strategic transaction timeline from the Maxim Group engagement increases the risk of prolonged uncertainty without near-term value realization. Regulatory pathways for both oncology and infectious disease indications remain unproven, with the Breakthrough Device designation only expediting FDA interaction without guaranteeing approval, and the open IDE status requiring successful completion of clinical trials before any PMA study can commence—each step fraught with potential failure due to device performance issues, patient enrollment challenges, or unforeseen regulatory changes. The company's dependence on emergency-use or compassionate-use protocols for Ebola deployment, as seen in the 2014 Frankfurt case, creates unreliable revenue streams and scalability challenges, particularly since no approved therapies exist for the Bundibugyo strain but widespread adoption would require overcoming significant logistical, institutional approval, and patient protection procedure hurdles in resource-constrained outbreak settings.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password